The seminal phase II trial reported that metastatic CRC with deficient DNA mismatch repair (dMMR) and MSI-high responds to programmed cell death 1 (PD-1) inhibitors while CRCs with proficient MMR and microsatellite stable (MSS) do not [4]. The gene discussed is PDCD1; the disease is colorectal carcinoma.